DCT

2:26-cv-02653

CMP Development LLC v. MSN Pharma Inc

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-02653, D.N.J., 07/28/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey based on Defendant MSN Pharmaceuticals, Inc.'s principal place of business in Piscataway, New Jersey, and its regular and continuous transaction of business in the state. The complaint also notes that Defendants have previously invoked the jurisdiction of this court in other patent cases.
  • Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's TADLIQ® product constitutes an act of infringement of five U.S. patents directed to liquid oral formulations of tadalafil.
  • Technical Context: The technology concerns stable, ready-to-use liquid oral suspensions of tadalafil, a drug for treating conditions like pulmonary arterial hypertension, designed to serve patients who have difficulty swallowing traditional solid dosage forms.
  • Key Procedural History: This is a patent infringement action filed under the Hatch-Waxman Act, triggered by Defendants' submission of ANDA No. 221209 seeking FDA approval to market a generic version of TADLIQ®. The ANDA included a Paragraph IV certification alleging the patents-in-suit are invalid, unenforceable, or would not be infringed.

Case Timeline

Date Event
2017-12-26 Priority Date for all Patents-in-Suit
2022-06-17 FDA Approval of Plaintiff's TADLIQ®
2022-07-12 U.S. Patent No. 11,382,917 Issues
2023-06-06 U.S. Patent No. 11,666,576 Issues
2024-05-07 U.S. Patent No. 11,975,006 Issues
2025-01-07 U.S. Patent No. 12,186,322 Issues
2026-01-23 Date of MSN's Notice Letter
2026-01-30 Plaintiff's Receipt of MSN's Notice Letter
2026-07-28 U.S. Patent No. 12,691,120 Issues
2026-07-28 Amended Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,382,917 - "Liquid Oral Formulations for Tadalafil"

  • Patent Identification: U.S. Patent No. 11,382,917, "Liquid Oral Formulations for Tadalafil," issued July 12, 2022.
  • The Invention Explained:
    • Problem Addressed: The patent addresses the technical challenge of formulating tadalafil, a drug with very low water solubility, into a liquid oral dosage form '917 Patent, col. 7:5-11 This is particularly difficult for patient populations, such as pediatrics and geriatrics, who may have trouble swallowing tablets and for whom existing powder-for-suspension products are inconvenient and difficult to prepare accurately '917 Patent, col. 7:12-19 '917 Patent, col. 9:11-25
    • The Patented Solution: The patent describes a stable, ready-to-use liquid oral suspension of tadalafil. The formulation uses a specific combination of excipients, including glycerin as a wetting agent to disperse the poorly soluble drug and a buffering agent to maintain the pH in a stable range (about 4 to 8), thereby preventing sedimentation and lumpiness without solubilizing the active ingredient '917 Patent, abstract '917 Patent, col. 13:17-30
    • Technical Importance: This invention provides a commercially viable, ready-to-use liquid formulation of tadalafil, which improves patient compliance, dosing accuracy, and convenience compared to either solid tablets or powders requiring reconstitution Compl. ¶9
  • Key Claims at a Glance:
    • The complaint does not specify asserted claims, but independent claim 1 is representative of the core invention.
    • The essential elements of independent claim 1 include:
      • A liquid oral pharmaceutical composition
      • Comprising about 4 mg/mL tadalafil
      • A pharmaceutically acceptable excipient
      • A vehicle comprising water
      • Wherein the composition has a pH from about 4 to 8
      • Wherein the excipient comprises a specific "anti-foaming agent" (e.g., simethicone) in a specified amount
    • The complaint reserves the right to assert additional claims Compl. ¶50

U.S. Patent No. 11,666,576 - "Liquid Oral Formulations for Tadalafil"

  • Patent Identification: U.S. Patent No. 11,666,576, "Liquid Oral Formulations for Tadalafil," issued June 6, 2023.
  • The Invention Explained:
    • Problem Addressed: Like its parent, the '576 Patent addresses the difficulty of creating a stable, palatable, and convenient liquid oral dosage form for the poorly soluble drug tadalafil '576 Patent, col. 7:5-11
    • The Patented Solution: The patent discloses a ready-to-use liquid oral suspension of tadalafil that achieves stability and palatability through a specific combination of excipients. This formulation focuses on the use of a "wetting agent" (such as glycerin) in combination with a preservative, sweetener, and flavorant to create a stable and patient-friendly product '576 Patent, abstract '576 Patent, col. 13:10-30
    • Technical Importance: The invention provides an alternative ready-to-use liquid tadalafil formulation, expanding options for patients with dysphagia and ensuring consistent dosing without complex preparation Compl. ¶9
  • Key Claims at a Glance:
    • The complaint does not specify asserted claims, but independent claim 1 is representative.
    • The essential elements of independent claim 1 include:
      • A liquid oral pharmaceutical composition
      • Comprising about 4 mg/mL tadalafil
      • A pharmaceutically acceptable excipient comprising a "wetting agent" (e.g., glycerin) in a specified amount
      • A vehicle comprising water
      • Wherein the composition has a pH from about 4 to 8
      • Wherein the excipient further comprises a preservative, a sweetener, and a flavorant in specified amounts
    • The complaint reserves the right to assert additional claims Compl. ¶58

Multi-Patent Capsule: U.S. Patent No. 11,975,006 - "Liquid Oral Formulations for Tadalafil"

  • Patent Identification: U.S. Patent No. 11,975,006, "Liquid Oral Formulations for Tadalafil," issued May 7, 2024.
  • Technology Synopsis: As a continuation in the same patent family, the '006 Patent addresses the same technical problem of creating a stable, ready-to-use liquid oral formulation for tadalafil. The solution again centers on a suspension using specific excipients, including a wetting agent, to manage the drug's low solubility '006 Patent, abstract '006 Patent, col. 13:10-30
  • Asserted Claims: The complaint alleges infringement of one or more claims Compl. ¶66
  • Accused Features: The entirety of Defendants' generic tadalafil liquid suspension product is accused of containing excipients that perform substantially the same function as the recited wetting agents in the patent's claims Compl. ¶65

Multi-Patent Capsule: U.S. Patent No. 12,186,322 - "Liquid Oral Formulations for Tadalafil"

  • Patent Identification: U.S. Patent No. 12,186,322, "Liquid Oral Formulations for Tadalafil," issued January 7, 2025.
  • Technology Synopsis: This patent, also in the same family, is directed to stable, liquid oral formulations of tadalafil. It solves the problem of tadalafil's poor solubility by creating a ready-to-use suspension with a specific combination of excipients, such as a wetting agent, to ensure proper dispersion and stability '322 Patent, abstract '322 Patent, col. 13:10-30
  • Asserted Claims: The complaint alleges infringement of one or more claims Compl. ¶74
  • Accused Features: Defendants' proposed generic product is alleged to contain the same active ingredient and excipients that function in substantially the same way as the wetting agents recited in the patent's claims Compl. ¶73

Multi-Patent Capsule: U.S. Patent No. 12,691,120 - "Liquid Oral Formulations for PDE V Inhibitors"

  • Patent Identification: U.S. Patent No. 12,691,120, "Liquid Oral Formulations for PDE V Inhibitors," issued July 28, 2026.
  • Technology Synopsis: This patent broadens the inventive concept to cover liquid oral formulations for the entire class of PDE V inhibitors, which includes tadalafil. It addresses the same core problem of formulating poorly soluble drugs into stable, ready-to-use liquid suspensions for patients who cannot take solid dosage forms, using a combination of excipients to achieve stability and palatability '120 Patent, abstract '120 Patent, col. 9:31-43
  • Asserted Claims: The complaint alleges infringement of one or more claims Compl. ¶81
  • Accused Features: Although the patent covers a class of drugs, the infringement allegation is specific to Defendants' tadalafil-based generic product. The complaint alleges this product contains excipients that perform substantially the same function as the wetting agents recited in the patent's claims Compl. ¶80

III. The Accused Instrumentality

  • Product Identification: The accused instrumentality is Defendants' proposed generic drug product, identified in Abbreviated New Drug Application (ANDA) No. 221209 ("the MSN ANDA Product") Compl. ¶2 Compl. ¶3
  • Functionality and Market Context:
    • The MSN ANDA Product is described as a ready-to-use, oral liquid suspension of tadalafil at a strength of 20 mg/5 mL Compl. ¶9 Compl. ¶36 It is intended for the same use as Plaintiff's TADLIQ® product, which is the treatment of pulmonary arterial hypertension to improve exercise ability Compl. ¶9 Compl. ¶42 The product is specifically designed as an alternative for patients with dysphagia (difficulty swallowing) who cannot take tablets Compl. ¶9 Compl. ¶40
    • The complaint alleges that the MSN ANDA Product will have the same active ingredient, dosage form, strength, and administration route as TADLIQ®, and that it will be bioequivalent Compl. ¶35 It is positioned to be a direct generic competitor to TADLIQ®, which the complaint asserts is the only FDA-approved ready-to-use oral suspension of tadalafil on the market Compl. ¶9

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

The complaint alleges infringement based on the composition of the MSN ANDA Product. Because the specific formulation details of the ANDA are confidential, the complaint pleads infringement "upon information and belief," asserting that the generic product contains excipients that perform "substantially the same function" in "substantially the same way" to achieve "substantially the same result" as the claimed excipients, which is language invoking the doctrine of equivalents Compl. ¶49 Compl. ¶57

11,382,917 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A liquid oral pharmaceutical composition, comprising: about 4 mg/mL tadalafil or a pharmaceutically acceptable salt thereof; The MSN ANDA Product is a liquid oral suspension containing tadalafil at the same 20 mg/5 mL strength (equivalent to 4 mg/mL). ¶36 col. 31:25-35
a pharmaceutically acceptable excipient; and a vehicle comprising water; wherein the pharmaceutical composition has a pH of from about 4 to about 8; The MSN ANDA Product is alleged to contain the same or substantially similar inactive ingredients as TADLIQ®, which is formulated in an aqueous vehicle at a stable pH. ¶38 col. 13:21-30
and wherein the pharmaceutically acceptable excipient comprises an anti-foaming agent comprising a simethicone, a simethicone emulsion, an organic phosphate, a paraffin oil, a stearate, a glycol, or a combination thereof, in an amount of from about 0.1 mg/mL to about 100 mg/mL. The complaint alleges, on information and belief, that the MSN ANDA Product contains an excipient or combination of excipients that performs substantially the same function as the recited anti-foaming agents. ¶49 col. 22:49-54

11,666,576 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A liquid oral pharmaceutical composition comprising about 4 mg/mL tadalafil or a pharmaceutically acceptable salt thereof; The MSN ANDA Product is a liquid oral suspension containing tadalafil at the same 20 mg/5 mL strength. ¶36 col. 32:9-11
a pharmaceutically acceptable excipient comprising a wetting agent comprising ethanol, glycerin, propylene glycol, or a combination thereof in an amount of about 100 mg/mL to about 1000 mg/mL; The complaint alleges, on information and belief, that the MSN ANDA Product contains an excipient or combination of excipients that performs substantially the same function as the recited wetting agents. ¶57 col. 18:14-37
and a vehicle comprising water; wherein the pharmaceutical composition has a pH of from about 4 to about 8; The MSN ANDA Product is an aqueous oral suspension alleged to be bioequivalent to TADLIQ® and formulated at a stable pH. ¶37; ¶38 col. 13:17-23
wherein the pharmaceutically acceptable excipient further comprises a preservative, a sweetener, a flavorant, or a combination thereof... The MSN ANDA Product is alleged to contain the same or substantially similar inactive ingredients as TADLIQ®, which includes such excipients for stability and palatability. ¶38 col. 13:40-52
  • Identified Points of Contention:
    • Equivalence of Excipients: A central point of contention will be whether the specific inactive ingredients in the MSN ANDA Product are legally equivalent to the claimed "anti-foaming agents" ('917 Patent) and "wetting agents" ('576 Patent). The complaint's reliance on "substantially the same function/way/result" language suggests this will be a primary battleground, hinging on a factual analysis under the doctrine of equivalents.
    • Pleading Sufficiency: An initial question for the court may be whether the complaint's allegations of infringement, made "on information and belief" without specifying the accused excipients, are sufficient to state a plausible claim for relief under the Twombly/Iqbal pleading standard, particularly in the context of a Hatch-Waxman action where the ANDA's contents are not yet public.

V. Key Claim Terms for Construction

  • The Term: "anti-foaming agent" ('917 Patent, claim 1)
  • Context and Importance: The infringement allegation for the '917 Patent hinges on whether an excipient in the MSN ANDA Product is equivalent to a claimed "anti-foaming agent" Compl. ¶49 The construction of this term will define the scope of potential equivalents and is therefore critical to the infringement analysis.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification provides a non-limiting list of examples, including "simethicone, organic phosphates, alcohols, paraffin oils, stearates, glycols and the like or any combinations thereof" '917 Patent, col. 22:49-54 Plaintiff may argue this supports a broad, functional definition covering any substance that reduces foam in the formulation.
    • Evidence for a Narrower Interpretation: The patent's sole working example uses a "30% Simethicone Emulsion" '917 Patent, Table 2 A party may argue that the term should be limited by this specific embodiment, especially in the context of achieving the overall stability of the claimed invention.
  • The Term: "wetting agent" '576 Patent, claim 1
  • Context and Importance: Practitioners may focus on this term because infringement of the '576 Patent is alleged based on the belief that the MSN ANDA Product contains an equivalent "wetting agent" Compl. ¶57 Its definition is central to determining whether the accused product falls within the claim scope, either literally or under the doctrine of equivalents.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification states that for an aqueous vehicle, "alcohol, glycerin, and PG are frequently used to facilitate the removal of adsorbed air from the surface of particles," and claim 1 itself lists "ethanol, glycerin, propylene glycol, or a combination thereof" '576 Patent, col. 18:21-24 '576 Patent, claim 1 This language may support a construction covering a class of functionally similar compounds.
    • Evidence for a Narrower Interpretation: The detailed examples exclusively use "Glycerin" as the wetting agent '576 Patent, Table 2 A party could argue that the term's meaning is informed by its role in achieving the specific, stable suspension described, potentially narrowing its scope to excipients that function identically to glycerin in that context.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon approval, Defendants will actively induce infringement by marketing the MSN ANDA Product for the same approved use as TADLIQ® Compl. ¶50 Compl. ¶58 The basis for this allegation is that the product's label and instructions will necessarily direct users and healthcare providers to administer the formulation, thereby infringing the patents.
  • Willful Infringement: The complaint alleges pre-suit knowledge of the patents, asserting that MSN had "actual and constructive knowledge" of the patents before submitting its ANDA Compl. ¶47 Compl. ¶55 This allegation is supported by the fact that MSN's ANDA included a Paragraph IV certification against the patents, which itself serves as evidence of knowledge. The complaint further alleges "specific intent to infringe" Compl. ¶51 Compl. ¶59

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of chemical and functional equivalence: does the specific combination of inactive ingredients in Defendants' ANDA submission perform substantially the same function, in substantially the same way, to achieve the same result as the "anti-foaming agents" and "wetting agents" recited in the patents-in-suit? This determination will likely require extensive fact discovery into the ANDA's formulation and expert testimony on pharmaceutical science.
  • A second key question will be one of claim construction: how broadly will the court define the key excipient terms? The case may turn on whether terms like "wetting agent" are construed as a broad functional category, or if they are interpreted more narrowly in light of the specific examples and the precise chemical environment required to achieve the stable suspension described in the patents.
  • A threshold procedural question is one of pleading sufficiency: given the confidential nature of the ANDA, are the complaint's infringement allegations, made "upon information and belief" and invoking the doctrine of equivalents without identifying the specific infringing excipients, plausible enough to survive a motion to dismiss under the heightened pleading standards of Twombly and Iqbal?
Loading Amended Complaint